Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
MINNETONKA, Minn., April 25, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products are scheduled to be presented at three upcoming professional meetings. The meetings include the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in Washington DC, May 1 - 4; the American Urological Association (AUA) Annual Meeting in Washington DC, May 14 -17; and the American Society of Colon & Rectal Surgeons (ASCRS) Annual Meeting in Vancouver, Canada, May 14 -18.
"There is a growing body of clinical evidence in support of our Urgent PC and Macroplastique products," said David Kaysen, President and CEO of Uroplasty. "This new data, along with previously published studies, confirms the efficacy and safety of both our products for the treatment of patients who suffer daily with overactive bladder or stress urinary incontinence."
ACOG PresentationsPercutaneous Tibial Nerve Stimulation vs. Validated Sham in those Exposed to Pharmacologic Therapy presented by Dr. Denise Elser, Illinois Urogynecology, Oak Lawn, IL Percutaneous Tibial Nerve Stimulation (PTNS) and the Effect on Fecal Incontinence* presented by Dr. Craig McCoy, Central Missouri Women's Healthcare, Marshall, MO
AUA PresentationsInsight into Percutaneous Tibial Nerve Stimulation: Critical Evaluation of the SUmiT Trial presented by Dr. Kenneth M. Peters, Beaumont Hospital, Royal Oak, MI Long-term Durability of Polydimethylsiloxane Injection for Female Stress Urinary Incontinence Correlates with Hi